Takeda Pharma Files 6-K Report
Ticker: TKPHF · Form: 6-K · Filed: Dec 8, 2025 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Dec 8, 2025 |
| Risk Level | low |
| Pages | 11 |
| Reading Time | 14 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, foreign-private-issuer
TL;DR
Takeda filed a 6-K on 12/8/25, confirming 20-F annual reports. Standard update.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on December 8, 2025, reporting as a foreign private issuer. The filing indicates Takeda will file its annual reports under Form 20-F. No specific financial or operational details beyond the filing type and date were provided in this excerpt.
Why It Matters
This filing serves as a routine update for investors and regulators, confirming Takeda's status and reporting schedule as a foreign private issuer.
Risk Assessment
Risk Level: low — This is a routine administrative filing by Takeda, not containing material new information that would typically impact risk.
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — Filer
- 0001395064-25-000164 (other) — Accession Number
- 20251208 (date) — Filing Date
- 001-38757 (other) — SEC File Number
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes public in its home country, files with a stock exchange, or distributes to its security holders.
Which annual report form does Takeda indicate it will file?
Takeda indicates it will file its annual reports under cover of Form 20-F.
What is Takeda's principal executive office address?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668, Japan.
What is the filing date of this Form 6-K?
This Form 6-K was filed on December 8, 2025.
Is Takeda submitting this Form 6-K in paper format?
The filing explicitly states that Takeda is not submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) or Rule 101(b)(7), indicated by unchecked boxes.
Filing Stats: 3,430 words · 14 min read · ~11 pages · Grade level 15.3 · Accepted 2025-12-08 06:02:38
Filing Documents
- form6k_120825.htm (6-K) — 65KB
- protagonist_logox120825.jpg (GRAPHIC) — 33KB
- takeda_logox120825.jpg (GRAPHIC) — 10KB
- 0001395064-25-000164.txt ( ) — 126KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date December 8, 2025 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller News Release Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera OSAKA, Japan, December 8, 2025 – Takeda (TSE4502NYSETAK) ("Takeda") and Protagonist Therapeutics, Inc. (NASDAQPTGX) announced on December 6, 2025 (ET), that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera were presented in an oral presentation at the 67th American Society of Hematology Annual Meeting and Exposition. For further details, please refer to the attached press release. The topline results of this study were announced on March 3, 2025, in "Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera". In addition, "Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera" was announced on June 2, 2025. Media Contact Investor Contact Emy Gruppo emy.gruppotakeda.com Christopher O'Reilly christopher.oreillytakeda.com The impact on Takeda's financial results for the fiscal year ending March 31, 2026 (FY2025), following the study results, is immaterial. ### News Release Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera 52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by A